C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/09 (2006.01) C07K 16/28 (2006.01) C12N 5/00 (2006.01) C12P 21/08 (2006.01) C12Q 1/02 (2006.01)
Patent
CA 2607147
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti- CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
La présente invention concerne des anticorps monoclonaux isolés, en particulier des anticorps monoclonaux humains, qui sont liés de manière spécifique à la MP-1 avec une grande affinité. L~invention concerne également des molécules d~acide nucléique codant les anticorps de l~invention, des vecteurs d~expression, des cellules hôtes et des procédés d~expression des anticorps de l~invention. L~invention concerne également des immunoconjugués, des molécules bispécifiques et des compositions pharmaceutiques comprenant les anticorps de l~invention. L~invention concerne en outre des procédés de détection de la MP1, ainsi que des procédés pour traiter diverses pathologies, dont le cancer et des maladies infectieuses, utilisant des anticorps anti-MP-1. La présente invention concerne en outre des procédés pour utiliser une combinaison d~immunothérapie, telle qu~une combinaison d~anti-CTLA-4 et d~anticorps anti-MP1, pour traiter une maladie hyperproliférative, telle qu~un cancer. L~invention concerne également des procédés destinés à modifier des événements indésirables liés au traitement avec de tels anticorps individuellement.
Carderelli Josephine M.
Chen Bing
Korman Alan J.
Selby Mark J.
Srinivasan Mohan
Medarex Inc.
Ono Pharmaceutical Co. Ltd.
Smart & Biggar
LandOfFree
Human monoclonal antibodies to programmed death 1(pd-1) and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies to programmed death 1(pd-1) and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to programmed death 1(pd-1) and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1895185